Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy

Blair McNamara; Stefania Bellone; Cem Demirkiran; Tobias Max Philipp Hartwich; Alessandro D Santin

doi:10.1016/j.gore.2023.101219

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy

Gynecol Oncol Rep. 2023 Jun 4:48:101219. doi: 10.1016/j.gore.2023.101219. eCollection 2023 Aug.

Authors

Blair McNamara¹, Stefania Bellone¹, Cem Demirkiran¹, Tobias Max Philipp Hartwich¹, Alessandro D Santin¹

Affiliation

¹ Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.

Abstract

Background: Treatment of uterine serous carcinoma (USC) is challenging; effective treatment options for metastatic and recurrent disease are needed.

Case: A 68-year-old woman with recurrent, metastatic, USC overexpressing HER2/neu experienced durable response to the antibody drug conjugate (ADC) trastuzumab-deruxtecan (T-DXd), after failing multiple standard and experimental treatments targeting HER2/neu. She experienced a significant reduction in disease burden, disappearance of metastatic back bone pain as well as normalization of CA-125 quickly after starting treatment. Her disease continued to show response to treatment over 5 months and 7 cycles of T-DXd therapy. She did not experience any dose-limiting side effects and tolerated treatment with 5.4 mg/kg T-DXd without issue.

Conclusion: T-DXd may present a new treatment option for chemotherapy-resistant uterine serous carcinoma.

Keywords: DS-8201a; HER2/neu; Trastuzumab deruxtecan; Uterine serous carcinoma.

Publication types

Case Reports

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States